Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04502589 · ClinicalTrials.gov registry record · Phase 1
Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
A Phase 1 study of Alcohol Disorders, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04502589 is a Phase 1 study of Alcohol Disorders that has completed, run by Virginia Commonwealth University. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04502589, a Phase 1 study of Alcohol Disorders, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug Perampanel when used in persons who drink and wish to stop drinking. Perampanel has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures but has not yet been approved to treat alcohol use disorders. For this reason, it is considered an investigational drug. Some people in this study will receive Perampanel alone and some people will receive Perampanel and Disulfiram, this will be determined by the pharmacy.
Conditions Studied
Interventions
- DRUG Disulfiram
- DRUG Perampanel Tablet
Study Locations (1)
Virginia
- Virginia Commonwealth University Inst. for Drug and Alcohol Studies - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-08-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04502589
The ClinicalTrials.gov registry entry for NCT04502589 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol Disorders appearing as the primary indexed condition, and to 2 interventions - of which Disulfiram is the first listed.
NCT04502589 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04502589 about?
NCT04502589 is a clinical study titled "Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder". The purpose of this research study is to test the safety, tolerability, and effectiveness of the drug Perampanel when used in persons who drink and wish to stop drinking. Perampanel has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures but has not yet been ap...
What is the current status of trial NCT04502589?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-10-15. Estimated completion is 2021-08-11.
What conditions does trial NCT04502589 study?
This clinical trial studies the following conditions: Alcohol Disorders.
What interventions are being tested in trial NCT04502589?
The interventions under investigation include: Disulfiram (DRUG), Perampanel Tablet (DRUG).
Who is sponsoring clinical trial NCT04502589?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04502589 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.